Macrophage-activating lipopeptide-2 (MALP-2), a TLR2/6 agonist, enhances NK cell cytotoxicity towards the tumor cells, while the PGE2 mediated immunosuppression was blocked by COX-2 inhibitor (78). Here, TLR2 is linked to neoplasm.